Yahoo · Oct 26, 2026
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know
Novavax (NVAX) concluded the recent trading session at $9.4, signifying a -3.09% move from its prior day's close.
NV
NASDAQ · NVAX
Novavax, Inc.
Healthcare · Biotechnology
$10.08
Down-$0.39 (-3.72%)
Updated Nov 1, 2026, 6:06 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.09B
- P/E ratio
- 3.18
- Dividend yield
- 0.00%
- 52-week range
- $6.20 – $13.39
- Volume
- 4.06M
- Avg. volume
- 4.26M
Price performance · NVAX
NVAX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
NVAX closed at $10.08 after 20 trading sessions, down 19.75% for the selected period.
- Last close
- $10.08
- Period change
- -19.75%
- Period low
- $9.40
- Period high
- $12.82
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $10.27 | $10.649 | $9.915 | $10.08 | 4.06M |
| Oct 29, 2026 | $10.19 | $10.62 | $10.185 | $10.47 | 2.8M |
| Oct 28, 2026 | $9.79 | $10.34 | $9.74 | $10.32 | 4.75M |
| Oct 27, 2026 | $9.37 | $10.10 | $8.9502 | $10.02 | 6.77M |
| Oct 26, 2026 | $9.56 | $9.88 | $9.26 | $9.40 | 4.94M |
| Oct 23, 2026 | $9.84 | $9.93 | $9.615 | $9.70 | 4.42M |
| Oct 22, 2026 | $10.79 | $10.865 | $9.555 | $9.99 | 12.25M |
| Oct 21, 2026 | $11.39 | $11.46 | $10.985 | $11.01 | 5.44M |
| Oct 20, 2026 | $10.75 | $11.57 | $10.55 | $11.43 | 6.53M |
| Oct 19, 2026 | $11.20 | $11.99 | $10.76 | $10.82 | 6.21M |
| Oct 16, 2026 | $12.71 | $12.84 | $11.1084 | $11.26 | 9.89M |
| Oct 15, 2026 | $12.50 | $13.25 | $12.18 | $12.82 | 7.37M |
| Oct 14, 2026 | $12.69 | $13.34 | $12.57 | $12.64 | 8.55M |
| Oct 13, 2026 | $12.44 | $13.125 | $12.21 | $12.82 | 8.4M |
| Oct 12, 2026 | $12.61 | $12.96 | $12.19 | $12.66 | 8.51M |
| Oct 9, 2026 | $11.17 | $13.04 | $11.03 | $12.75 | 19.03M |
| Oct 8, 2026 | $11.01 | $11.18 | $10.76 | $11.01 | 6.21M |
| Oct 7, 2026 | $11.01 | $11.75 | $10.90 | $11.22 | 8.38M |
| Oct 6, 2026 | $12.35 | $13.33 | $10.88 | $11.32 | 19.41M |
| Oct 5, 2026 | $10.47 | $13.385 | $10.275 | $12.56 | 28.7M |
Latest NVAX news
The latest Smart Investors Daily articles mentioning NVAX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
NVAX research
Overview
Company profile and research snapshot.
Company profile
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $14.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2026 | Citigroup | Sell | — |
| Jun 11, 2026 | BTIG | Buy | — |
| May 6, 2026 | TD Cowen | Hold | — |
| Feb 27, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 20, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 24, 2026
What Novavax Doubters Overlooked
If you backed Novavax at the start of the year, the story looks very different now than it did on day one. For Novavax shareholders, the return from the start of the year was 36.0%, including dividends. If that decision sat in front of you again, you would be weighing a sharp revenue pullback, a fresh licensing model, and divided analyst targets. Were early buyers really paying for partnership optionality, or underestimating how narrow the vaccine portfolio had become? The move put Novavax in...
Yahoo · Oct 23, 2026
Is Novavax (NVAX) Fully Priced Relative To Its Sales Base?
Novavax has had a volatile few years, and the share price history raises a straightforward question for you as an investor. Is the current US$9.99 price tag adequately supported by the company’s sales, or is the market expecting more revenue than the business is currently set up to deliver? The stock has fallen 93.4% over the past 5 years. This puts the focus squarely on whether today’s valuation can still be explained by its underlying sales base. The business depends heavily on turning its...
Yahoo · Oct 23, 2026
Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?
Biogen (BIIB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
